Zura Bio Limited (NASDAQ:ZURA) Short Interest Update

Zura Bio Limited (NASDAQ:ZURA) was the target of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 428,400 shares, a drop of 31.8% from the March 31st total of 628,300 shares. Currently, 2.3% of the company’s shares are sold short. Based on an average daily trading volume, of 295,200 shares, the days-to-cover ratio is currently 1.5 days.

Analysts Set New Price Targets

Separately, Oppenheimer reiterated an “outperform” rating and set a $16.00 price objective (down from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $16.40.

Insider Buying and Selling

In other Zura Bio news, Director Amit Munshi bought 159,744 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The stock was purchased at an average price of $3.13 per share, with a total value of $499,998.72. Following the transaction, the director now owns 777,384 shares in the company, valued at $2,433,211.92. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have bought 170,926 shares of company stock valued at $534,998. 15.80% of the stock is currently owned by company insiders.

Institutional Trading of Zura Bio

Several large investors have recently added to or reduced their stakes in the business. Lynx1 Capital Management LP bought a new stake in shares of Zura Bio during the 3rd quarter worth about $65,000. Forefront Analytics LLC acquired a new position in shares of Zura Bio during the third quarter valued at approximately $95,000. Bank of New York Mellon Corp bought a new stake in Zura Bio during the third quarter worth approximately $224,000. Raymond James & Associates lifted its position in Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after purchasing an additional 9,481 shares during the period. Finally, Eisler Capital US LLC bought a new position in Zura Bio during the 3rd quarter valued at $660,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Stock Performance

NASDAQ ZURA opened at $4.41 on Monday. The company has a 50-day moving average price of $3.19 and a two-hundred day moving average price of $3.97. Zura Bio has a 52 week low of $2.00 and a 52 week high of $14.00.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.